BeyondSpring Inc. (BYSI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for BeyondSpring Inc. in 2026. The next earnings report is expected on September 4, 2026.
Next earnings date
04 Sep 2026
In 16 days
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
BeyondSpring Inc. (BYSI) is scheduled to report earnings on September 4, 2026.
BeyondSpring Inc. (BYSI) last reported earnings on August 14, 2026.
BeyondSpring Inc. (BYSI) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.